Milestone Pharmaceuticals Induces Employee Stock Options

MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 123,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of three new employees. 

Milestone Pharmaceuticals has recently announced a significant development regarding its employee stock options and grants, as stipulated under Nasdaq Listing Rule 5635(c)(4). This regulatory action reflects the company's ongoing commitment to rewarding its workforce as it continues to grow and innovate in the pharmaceutical sector.

The inducement grants consist of stock options awarded to 15 new employees who have joined Milestone Pharmaceuticals. Each recipient will receive options for 75,000 shares of the company's common stock, with a term of ten years. The exercise price for these stock options is set at $10.26, reflecting the closing price of Milestone's common stock on April 1, 2026.

This move is not only a strategic recruitment tool but also highlights Milestone's focus on building a strong team that can drive the company's vision forward, aligning the interests of employees with those of shareholders. Incentives such as stock options are crucial in attracting top talent, particularly in the competitive landscape of biopharmaceuticals.

Milestone Pharmaceuticals is known for its dedication to developing innovative therapeutic solutions for cardiovascular diseases, and the induction of new talent will play a pivotal role in achieving its future goals. In the context of the ever-evolving biopharma industry, fostering a motivated workforce through equity compensation is increasingly recognized as a best practice.

Furthermore, the company's strategic alignment of its human resources practices with shareholder interests is indicative of a broader trend in the industry where companies leverage stock options as a means of enhancing engagement and performance among their teams. It is a strategic approach to ensure that employees are personally invested in the company's success, which can translate into increased productivity and innovation.

As Milestone Pharmaceuticals continues to expand its pipeline and prepare for future clinical trials, the induction of new employees through stock options will enable the company to enhance its capability to deliver groundbreaking treatments. This announcement underscores the organization's commitment to building a robust operational capacity that can support its developmental ambitions in the biopharmaceutical arena.

In conclusion, Milestone Pharmaceuticals’ recent stock options grants underlines the importance of aligning employee incentives with company performance, fostering a culture of shared success and collaboration. As the industry faces ongoing challenges and opportunities, these strategies will be crucial in positioning the company for sustainable growth and innovation in the biopharmaceutical market.